Name (Print/Type)

Signature

	ج
兄	2
₹	9
	S.U
⋈	<u>.</u>
ð	겆
_	J

Please type a plus sign (+) inside this box — 🔭

PTO/SB/05 (03-01) Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Attornev Docket No.

First Inventor

UTILITY PATENT APPLICATION TRANSMITTAL

DYX-016.1 US

03 April 2001

Date

Rondon & Ladner BINDING PEPTIDES FOR

Title CARCINOEMBRYONIC ANTIGEN (CEA)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

EL 164335061 US Express Mail Label No.

Assistant Commissioner for Patents APPLICATION ELEMENTS ADDRESS TO: Box Patent Application Washington, DC 20231 See MPEP chapter 600 concerning utility patent application contents. Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or (Submit an original and a duplicate for fee processing) Computer Program (Appendix) Applicant claims small entity status. 8. Nucleotide and/or Amino Acid Sequence Submission See 37 CFR 1.27. (if applicable, all necessary) Specification [Total Pages (preferred arrangement set forth below) a. Computer Readable Form (CRF) 3. [X - Descriptive title of the invention b. Specification Sequence Listing on: Cross Reference to Related Applications i. CD-ROM or CD-R (2 copies); or Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix c. X Statements verifying identity of above copies - Background of the Invention - Brief Summary of the Invention ACCOMPANYING APPLICATION PARTS - Brief Description of the Drawings (if filed) - Detailed Description Assignment Papers (cover sheet & document(s)) 9. - Claim(s) Power of 37 CFR 3.73(b) Statement 10. - Abstract of the Disclosure Attorney (when there is an assignee) 11. English Translation Document (if applicable) 4. **X** Drawing(s) (35 U.S.C. 113) [Total Sheets Copies of IDS Information Disclosure 12. 🗶 Citations [Total Pages 5. Oath or Declaration Statement (IDS)/PTO-1449 **Preliminary Amendment** 13. Newly executed (original or copy) Copy from a prior application (37 CFR 1.63 (d)) (for continuation/divisional with Box 18 completed) Return Receipt Postcard (MPEP 503) 14. **X** (Should be specifically itemized) Certified Copy of Priority Document(s) (if foreign priority is claimed) **DELETION OF INVENTOR(S)** 15. Signed statement attached deleting inventor(s) Nonpublication Request under 35 U.S.C. 122 named in the prior application, see 37 CFR 16. (b)(2)(B)(i). Applicant must attach form PTO/SB/35 1 63(d)(2) and 1.33(b). or its equivalent. Application Data Sheet. See 37 CFR 1.76 17. Other: 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: 541,345 Continuation-in-part (CIP) of prior application No. _ Divisional Continuation Examiner_ (not known) Group Art Unit: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS X Correspondence address below Customer Number or Bar Code Label (Insert Customer No. or Attach har code label here) Leon R. Yankwich, Esq. Name YANKWICH & ASSOCIATES 130 Bishop Allen Drive Address Zip Code State Massachusetts 02139 Cambridge City (617) 491-8801 (617) 491-4343 Fax U.S.A. Telephone Country 43,310 Registration No. (Attorney/Agent) Kenneth P. Zwicker

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Rondon & Ladner

Serial No.:

(not yet assigned)

Filed:

(concurrently herewith)

Entitled:

BINDING PEPTIDES FOR CARCINOEMBRYONIC

ANTIGEN (CEA)

CIP of U.S. Appln. Ser. No. 09/541,345, pending

Attorney Docket No.: DYX-016.1 US

Asst. Commissioner for Patents

Box Patent Application

Washington, D.C. 20231

& Ox Segr

Art Unit: (not yet assigned)

Examiner: (not yet known)



UTILITY PATENT APPLICATION TRANSMITTAL:

Continuation-In-Part of U.S. Appln. Ser. No. 09/541,345, pending Prior Examiner: (not yet known) Prior Unit: 1646

1. Fee Transmittal form PTO/SB/17 (in duplicate).

2. Utility Patent Application Transmittal form PTO/SB/05.

- 3. Application specification of <u>56</u> pages (including Claims and Abstract of the Disclosure).
- 4. Formal drawings (8 sheets).
- 5. Unexecuted Inventor's combined declaration for patent and power of attorney.
- 6. Sequence Listing;
 - (a) computer readable form (CRF), (b) paper copy, and (c) statement under 37 CFR 1.821(f).
- 7. Information Disclosure Statement (including form PTO-1449).
- 8. Return receipt post card.
- 9. Check No. 2178 in the amount of \$ 2016.00 to cover the application filing fee.

Respectfully submitted

Leon R. Yankwish: Registration No. 30,237

Kenneth P. Zwicker, PhD; Registration No. 43,310

Attorneys for Applicant

YANKWICH & ASSOCIATES

130 Bishop Allen Drive

Cambridge, Massachusetts 02139

telephone: (617) 491-4343 telefax: (617) 491-8801

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

The undersigned hereby certifies that this correspondence listed above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR §1.10, postage prepaid, Express Mailing Label No. EL 164335061 US, in an envelope addressed to the Asst. Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on the date indicated below.

03 April 2001

Date

Stephanie A. Seicht
Stephanie L. Leicht

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

2016.00 (\$)

Complete if Known			
Application Number (not yet assigned)			
Filing Date	(concurrently herewith)		
First Named Inventor	Rondon & Ladner		
Examiner Name	(not known)		
Group Art Unit	1646		
Attorney Docket No.	DYX-016.1 US		

METHOD OF PAYMENT	FEE CALCULATION (continued)					
The Commissioner is hereby authorized to charge	3. ADDITIONAL FEES					
1. Indicated fees and credit any overpayments to:	Large Small					
Deposit Account Number 50-0268	Entity Entity Fee Fee Fee Fee Fee Description Fee Paid					
Deposit Account Yankwich & Associates	Code (\$) Code (\$) 105 130 205 65 Surcharge - late filing fee or oath					
Name	127 50 227 25 Surcharge - late provisional filing fee or					
Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	cover sheet					
Applicant claims small entity status.	139 130 139 130 Non-English specification					
See 37 CFR 1.27	147 2,520 147 2,520 For filing a request for ex parte reexamination					
2. X Payment Enclosed: (check # 2178) X Check Credit card Money Order Other	112 920* 112 920* Requesting publication of SIR prior to Examiner action					
FEE CALCULATION	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action					
1. BASIC FILING FEE	115 110 215 55 Extension for reply within first month					
1. BASIC FILING FEE Large Entity Small Entity	116 390 216 195 Extension for reply within second month					
Fee Fee Fee Fee Description	117 890 217 445 Extension for reply within third month					
Code (\$)	118 1,390 218 695 Extension for reply within fourth month					
101 710 201 355 Utility filing fee 710.00	128 1,890 228 945 Extension for reply within fifth month					
	119 310 219 155 Notice of Appeal					
107 490 207 245 Plant filing fee 108 710 208 355 Reissue filing fee	120 310 220 155 Filing a brief in support of an appeal					
	121 270 221 135 Request for oral hearing					
	138 1,510 138 1,510 Petition to institute a public use proceeding					
SUBTOTAL (1) (\$) 710.00	140 110 240 55 Petition to revive - unavoidable					
2. EXTRA CLAIM FEES	141 1,240 241 620 Petition to revive - unintentional					
Fee from Extra Claims below Fee Paid	142 1,240 242 620 Utility issue fee (or reissue)					
Total Claims 42 -20** = 22 x 18.00 = 396.00	143 440 243 220 Design Issue fee					
Independent 11 - 3** = 8 X 80.00 = 640.00	144 600 244 300 Plant issue fee					
Multiple Dependent 270.00 = 270.00	122 130 122 130 Petitions to the Commissioner					
	123 50 123 50 Processing fee under 37 CFR 1 17(q)					
Large Entity Small Entity	126 180 126 180 Submission of Information Disclosure Stmt					
Fee Fee Fee Fee Fee Description Code (\$) Code (\$) 103 18 203 9 Claims in excess of 20	581 40 581 40 Recording each patent assignment per property (times number of properties)					
103 18 203 9 Claims in excess of 20 102 80 202 40 Independent claims in excess of 3	146 710 246 355 Filing a submission after final rejection (37 CFR § 1.129(a))					
104 270 204 135 Multiple dependent claim, if not paid						
109 80 209 40 ** Reissue independent claims over original patent	examined (37 CFR § 1.129(b))					
110 18 210 9 ** Reissue claims in excess of 20	179 710 279 355 Request for Continued Examination (RCE)					
and over original patent	169 900 169 900 Request for expedited examination of a design application					
SUBTOTAL (2) (\$)1306.00	Other fee (specify)					
**or number previously paid, if greater; For Reissues, see above *Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)						

SUBMITTED BY			Complete (if applicable)		
Name (PrintlType)	Kenpeth P. Zwicker	Registration No. (Attorney/Agent)	43,310	Telephone	(617) 491-4343
Signature	Ren Justine	patomojnigom		Date	03 April 2001

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Rondon & Ladner

Serial No.:

(not yet assigned)

Filed:

(concurrently herewith)

Entitled:

BINDING PEPTIDES FOR

CARCINOEMBRYONIC

ANTIGEN (CEA)

CIP of U.S. Appln. Ser. No. 09/541,345, pending

Attorney Docket No.: DYX-016.1 US

Art Unit: (not yet assigned)

Examiner: (not yet assigned)

Assistant Commissioner for Patents **Box Patent Application** Washington, D.C. 20231

<u>Transmittal of Sequence Listing, Computer Readable Form, and Amendment Pertaining</u> <u>Thereto For Invention Containing Nucleotide and/or Amino Acid Sequence</u> <u>Under 37 CFR §§1.821-1.825</u>

Sir:

Transmitted herewith please find: a diskette containing a computer readable form (CRF) copy of the Sequence Listing, and a paper copy of the Sequence Listing for the patent application filed currently herewith this paper.

Applicant has assigned a separate identifier to each of the 151 sequences disclosed, as required by 37 CFR §§1.821-1.825.

Applicant verifies the following:

- 1. The enclosed Sequence Listing and the computer readable form of the Sequence Listing for the above-identified patent application are the same in content, as required by 37 CFR §1.821(f);
- The enclosed Sequence Listing and the computer readable form of the Sequence Listing
 for the above-identified patent application contain no new matter and do not go
 beyond the original disclosure of the application, as required by 37 CFR §1.821(g);

٠. ١

3. The enclosed Sequence Listing and the computer readable form of the Sequence Listing for the above-identified patent application are in a form and format in accordance with 37 CFR §§1.822, 1.823, and 1.824.

Respectfully submitted,

Leon R. Yankwich; Registration No. 30,237

Kenneth P. Zwicker, PhD; Registration No. 43,310

Attorneys for Applicant

YANKWICH & ASSOCIATES

130 Bishop Allen Drive

Cambridge, Massachusetts 02139

telephone: (617) 491-4343 telefax: (617) 491-8801

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

The undersigned hereby certifies that this correspondence listed above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR §1.10, postage prepaid, Express Mailing Label No. **EL 164335061 US**, in an envelope addressed to the Asst. Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on the date indicated below.

03 April 2001

Date

Stephanie L. Leicht